FI3692023T3 - Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon - Google Patents
Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon Download PDFInfo
- Publication number
- FI3692023T3 FI3692023T3 FIEP18864678.0T FI18864678T FI3692023T3 FI 3692023 T3 FI3692023 T3 FI 3692023T3 FI 18864678 T FI18864678 T FI 18864678T FI 3692023 T3 FI3692023 T3 FI 3692023T3
- Authority
- FI
- Finland
- Prior art keywords
- yyli
- karboksamidi
- bentso
- fluori
- tiatsol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762566649P | 2017-10-02 | 2017-10-02 | |
| US201862666800P | 2018-05-04 | 2018-05-04 | |
| US201862696432P | 2018-07-11 | 2018-07-11 | |
| PCT/KR2018/011660 WO2019070093A1 (en) | 2017-10-02 | 2018-10-01 | BENZOTHIAZOL COMPOUNDS AND METHODS OF USING THE SAME FOR TREATING NEURODEGENERATIVE DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3692023T3 true FI3692023T3 (fi) | 2023-08-17 |
Family
ID=65897719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18864678.0T FI3692023T3 (fi) | 2017-10-02 | 2018-10-01 | Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10669246B2 (enExample) |
| EP (1) | EP3692023B1 (enExample) |
| JP (2) | JP2020536116A (enExample) |
| KR (1) | KR102858188B1 (enExample) |
| CN (1) | CN111315727B (enExample) |
| AU (1) | AU2018346051B2 (enExample) |
| CA (1) | CA3078173A1 (enExample) |
| ES (1) | ES2953025T3 (enExample) |
| FI (1) | FI3692023T3 (enExample) |
| HU (1) | HUE062526T2 (enExample) |
| IL (1) | IL273705B2 (enExample) |
| MX (1) | MX2020003593A (enExample) |
| PL (1) | PL3692023T3 (enExample) |
| PT (1) | PT3692023T (enExample) |
| WO (1) | WO2019070093A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102858188B1 (ko) | 2017-10-02 | 2025-09-11 | 주식회사 퍼스트바이오테라퓨틱스 | 벤조티아졸 화합물 및 신경퇴행성 질환을 치료하기 위한 그의 사용 방법 |
| EP3927705A4 (en) | 2019-02-22 | 2022-12-07 | 1st Biotherapeutics, Inc. | IMIDAZOPYRIDINYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| KR20210126146A (ko) * | 2019-03-07 | 2021-10-19 | 주식회사 퍼스트바이오테라퓨틱스 | Pet 방사선추적자로서의 [18f]-라벨링된 벤조티아졸 유도체 |
| US10385046B1 (en) * | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
| JP7604387B2 (ja) * | 2019-03-28 | 2024-12-23 | ファースト・バイオセラピューティクス・インコーポレイテッド | ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法 |
| CN110483402B (zh) * | 2019-08-12 | 2021-07-23 | 上海毕得医药科技股份有限公司 | 一种3-溴-5-苯基-1h-吡唑的合成方法 |
| EP4200299A4 (en) | 2020-08-21 | 2024-09-25 | 1st Biotherapeutics, Inc. | COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS |
| JP7773233B2 (ja) * | 2020-08-21 | 2025-11-19 | ファースト・バイオセラピューティクス・インコーポレイテッド | Ｐｅｔ放射性トレーサとしての［１８ｆ］標識イミダゾピリジン誘導体 |
| WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
| EP4223750B1 (en) * | 2020-09-30 | 2025-06-25 | Asahi Kasei Pharma Corporation | Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases |
| TWI898106B (zh) * | 2022-01-11 | 2025-09-21 | 日商旭化成製藥股份有限公司 | 含有嘧啶之含氮雙環化合物 |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1187453A (en) * | 1915-09-20 | 1916-06-13 | Allis Chalmers Mfg Co | Steam-turbine. |
| US2258671A (en) * | 1940-01-27 | 1941-10-14 | Nat Oil Prod Co | Refining of fat-soluble vitamincontaining materials |
| IL135176A0 (en) * | 1997-11-10 | 2001-05-20 | Bristol Myers Squibb Co | Benzothiazole derivatives and pharmaceutical compositions containing the same |
| AU2001236698A1 (en) | 2000-02-07 | 2001-08-14 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| CN101384586A (zh) * | 2006-02-14 | 2009-03-11 | 诺华公司 | Pi-3激酶抑制剂及其应用方法 |
| JPWO2008016131A1 (ja) | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| AR067562A1 (es) | 2007-07-18 | 2009-10-14 | Novartis Ag | Compuestos heterociclicos inhibidores de kinasa |
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| WO2009114874A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
| JP2011525535A (ja) | 2008-06-24 | 2011-09-22 | 武田薬品工業株式会社 | ＰＩ３Ｋ／ｍＴＯＲ阻害剤 |
| US9096611B2 (en) * | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
| JP4528849B2 (ja) * | 2008-07-14 | 2010-08-25 | シャープ株式会社 | 引出し型加熱調理器 |
| WO2010100144A1 (en) * | 2009-03-04 | 2010-09-10 | Merck Serono S.A. | Fused bicyclic compounds as inhibitors for pi3 kinase |
| EP2440058A4 (en) | 2009-06-12 | 2012-11-21 | Dana Farber Cancer Inst Inc | MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| PH12013501489A1 (en) * | 2010-12-17 | 2013-08-28 | Hoffmann La Roche | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| KR20140107153A (ko) * | 2014-07-23 | 2014-09-04 | 한국과학기술원 | 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물 |
| KR102858188B1 (ko) | 2017-10-02 | 2025-09-11 | 주식회사 퍼스트바이오테라퓨틱스 | 벤조티아졸 화합물 및 신경퇴행성 질환을 치료하기 위한 그의 사용 방법 |
-
2018
- 2018-10-01 KR KR1020207012653A patent/KR102858188B1/ko active Active
- 2018-10-01 CA CA3078173A patent/CA3078173A1/en active Pending
- 2018-10-01 JP JP2020520037A patent/JP2020536116A/ja active Pending
- 2018-10-01 EP EP18864678.0A patent/EP3692023B1/en active Active
- 2018-10-01 US US16/148,265 patent/US10669246B2/en active Active
- 2018-10-01 ES ES18864678T patent/ES2953025T3/es active Active
- 2018-10-01 FI FIEP18864678.0T patent/FI3692023T3/fi active
- 2018-10-01 MX MX2020003593A patent/MX2020003593A/es unknown
- 2018-10-01 AU AU2018346051A patent/AU2018346051B2/en active Active
- 2018-10-01 CN CN201880063869.7A patent/CN111315727B/zh active Active
- 2018-10-01 WO PCT/KR2018/011660 patent/WO2019070093A1/en not_active Ceased
- 2018-10-01 HU HUE18864678A patent/HUE062526T2/hu unknown
- 2018-10-01 PL PL18864678.0T patent/PL3692023T3/pl unknown
- 2018-10-01 PT PT188646780T patent/PT3692023T/pt unknown
-
2020
- 2020-03-30 IL IL273705A patent/IL273705B2/en unknown
- 2020-05-14 US US15/931,827 patent/US10968188B2/en active Active
-
2023
- 2023-05-15 JP JP2023080175A patent/JP7605898B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018346051A1 (en) | 2020-04-09 |
| CA3078173A1 (en) | 2019-04-11 |
| WO2019070093A1 (en) | 2019-04-11 |
| EP3692023A1 (en) | 2020-08-12 |
| CN111315727B (zh) | 2023-09-29 |
| PT3692023T (pt) | 2023-08-23 |
| EP3692023B1 (en) | 2023-05-17 |
| JP2023109868A (ja) | 2023-08-08 |
| PL3692023T3 (pl) | 2023-12-11 |
| US20200270222A1 (en) | 2020-08-27 |
| IL273705A (en) | 2020-05-31 |
| RU2020112784A (ru) | 2021-11-09 |
| EP3692023A4 (en) | 2021-04-07 |
| JP2020536116A (ja) | 2020-12-10 |
| KR20200051832A (ko) | 2020-05-13 |
| CN111315727A (zh) | 2020-06-19 |
| AU2018346051B2 (en) | 2022-11-10 |
| HUE062526T2 (hu) | 2023-11-28 |
| RU2020112784A3 (enExample) | 2022-03-05 |
| US10669246B2 (en) | 2020-06-02 |
| IL273705B2 (en) | 2023-02-01 |
| US20190100500A1 (en) | 2019-04-04 |
| IL273705B (en) | 2022-10-01 |
| US10968188B2 (en) | 2021-04-06 |
| MX2020003593A (es) | 2020-07-22 |
| ES2953025T3 (es) | 2023-11-07 |
| KR102858188B1 (ko) | 2025-09-11 |
| JP7605898B2 (ja) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3692023T3 (fi) | Bentsotiatsoliyhdisteitä ja menetelmiä niiden käyttämiseksi neurodegeneratiivisten häiriöiden hoitoon | |
| IL288104A (en) | Heterocyclic compounds, preparation methods and their use | |
| IL288236A (en) | 3,2-dihydroquinazoline compounds as inhibitors of nav1.8 | |
| MX379169B (es) | Amidas heterocíclicas útiles como moduladores de proteínas. | |
| WO2018042343A3 (en) | Compounds that inhibit 3c and 3cl proteases and methods of use thereof | |
| WO2018006074A3 (en) | Compounds and methods for modulating rna function | |
| EP3919055A4 (en) | HETEROCYCLIC COMPOUND | |
| EP3317282A4 (en) | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | |
| EP3860571A4 (en) | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
| WO2017156495A8 (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
| EP4013428A4 (en) | MODIFIED OLIGOMER COMPOUNDS AND USES THEREOF | |
| EP3741753A4 (en) | SUBSTITUTED DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND AND COMPOSITION CONTAINING THE COMPOUND AND ITS USE | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| WO2020127259A3 (en) | Materials for electronic devices | |
| SG11201901773QA (en) | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | |
| IL299303B2 (en) | History of 5,3,2-tetrahydro-2h-inazol-3-ol | |
| PL3430113T3 (pl) | Sposób kontrolowania nieprzyjemnego zapachu „potu” z zastosowaniem przetrwalników bakterii zdolnych do hamowania lub zapobiegania tworzeniu się takiego nieprzyjemnego zapachu | |
| EP3863631A4 (en) | PYRIMIDINE AND PYRAZINE HDAC 1, 2 INHIBITORS | |
| WO2018211323A8 (en) | Heterocyclic compounds for the treatment of disease | |
| WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
| EP3541801A4 (en) | 4- (6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H | |
| EP3585309A4 (en) | EYE DEVICES AND THEIR METHODS OF USE | |
| WO2018146390A8 (fr) | Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer | |
| EP3759079A4 (en) | AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE | |
| EP3699287A4 (en) | 1,5-DIAMINOPENTANE PURIFICATION PROCESS |